Mersana Therapeutics to Present at Upcoming Investor Conferences
Mersana Therapeutics (NASDAQ: MRSN), a clinical-stage biopharmaceutical company, will present at several upcoming investor conferences in February and March 2023.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Mersana Therapeutics (NASDAQ: MRSN), a clinical-stage biopharmaceutical company, will present at several upcoming investor conferences in February and March 2023. Key events include:
- Guggenheim Oncology Conference: Feb 8, 2023, at 2:10 p.m. ET
- SVB Securities Global Biopharma Conference: Feb 15, 2023, at 1:00 p.m. ET
- Cowen 43rd Annual Health Care Conference: Mar 8, 2023, at 9:10 a.m. ET
- Oppenheimer 33rd Annual Healthcare Conference: Mar 14, 2023, at 12:00 p.m. ET
Live webcasts will be available on Mersana’s website, with archived replays for 90 days.
Details
News Market Reaction – MRSN
The recorded move for MRSN in the trading session of this news was +2.53%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the following upcoming investor conferences:
| Guggenheim Oncology Conference | |
| Format: | Fireside Chat |
| Date/Time: | Wednesday, February 8, 2023, at 2:10 p.m. Eastern Time |
| SVB Securities Global Biopharma Conference | |
| Format: | Fireside Chat |
| Date/Time | Wednesday, February 15, 2023, at 1:00 p.m. Eastern Time |
| Cowen 43rd Annual Health Care Conference | |
| Format: | Panel Discussion |
| Date/Time: | Wednesday, March 8, 2023, at 9:10 a.m. Eastern Time |
| Oppenheimer 33rd Annual Healthcare Conference | |
| Format: | Presentation |
| Date/Time: | Tuesday, March 14, 2023, at 12:00 p.m. Eastern Time |
Live webcasts of these events will be available on the Investors & Media section of Mersana’s website at www.mersana.com. Archived replays will be available for approximately 90 days following the events.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b that is being studied in UPLIFT, a single-arm registrational trial in patients with platinum-resistant ovarian cancer; UPGRADE-A, a Phase 1 clinical trial evaluating UpRi in combination with carboplatin; and UP-NEXT, a Phase 3 clinical trial of UpRi as monotherapy maintenance following treatment with platinum doublets in recurrent platinum-sensitive ovarian cancer. Mersana is also advancing XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets. In addition, multiple partners are using Mersana’s platforms to advance their ADC pipelines. Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.
Contact:
Jason Fredette
617-498-0020
jason.fredette@mersana.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.